Overview

Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

In the second-line treatment setting for MBC, many agents, including antitubulin drugs (Taxanes, Vinorelbine) and antimetabolites (Capecitabine, Gemcitabine), have demonstrated activity, but no agent is clearly superior. Although some combinations of cytotoxic agents provide a small progression-free survival advantage, none has demonstrated an OS advantage, and toxicity is generally greater than for single agents. At present, there is no standard for this treatment setting. New treatments that could delay disease progression without systemic toxicity would represent a significant advancement.

Phase:

Phase 2

Details

Lead Sponsor:

Consorzio Oncotech

Collaborator:

Clinical Research Technology S.r.l.

Treatments:

Bevacizumab